NASDAQ
56.12USD
-1.20 (-2.10%)
We have scored 57 news catalysts on CRISPR Therapeutics AG (CRSP) over the past 12 months. The biggest single-day move next to one of them came Jul 4, 2026, when CRSP closed +8.0%: “Dow Jones and S&P 500 Forecast: Tariffs Test Rally as Dow Targets 55,000”. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.4B
P/E
—
EPS
—
Beta
1.76
52W range
44.12-78.48
Day range
55.63–59.34
Open
58.00
Prev close
57.33
Volume
346.9K
Avg volume
1.6M
Dividend
0.00
IPO
2016-10-19
Analysts publish price targets on CRSP, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $55 to $80
as of 2026-09-05
The market is 18% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about CRISPR Therapeutics AG — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of CRISPR Therapeutics AG, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for CRSP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
The price sits 18% below the median analyst target and at the 17th percentile of the published spread, meaning the market believes the current cash reserves and approved therapy but refuses to pay for the pipeline's potential upside.
What the disagreement turns on
Whether the early clinical data for CTX310 and Zugo-cel will translate into viable, high-value therapies, a question that available wired data cannot settle because it requires clinical trial outcomes rather than consumer or volume metrics.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
